Key Highlights

  • Third-quarter Revenue was USD 38,110, mainly from the AI segment.
  • Net loss was USD 3.4 million versus USD 1.2 million a year earlier.
  • Nine-month Goodwill Impairment was USD 10.1 million.
  • Cash was USD 239,834 at September 30, 2026.

A New Revenue Line and a Wider Loss

GridAI Technologies Corp. (NASDAQ:GRDX), formerly Entero Therapeutics, reported third-quarter revenue of USD 38,110 versus none a year earlier, and USD 162,194 for the nine months, which the filing attributes primarily to the AI segment. Cost of services was USD 30,849 in the quarter, leaving Gross Profit of USD 7,261, while the nine-month figure showed a gross loss of USD 642,993 on cost of services of USD 805,187.

General and administrative expense was USD 3,637,709 versus USD 928,114 in the quarter, and total operating expenses were USD 3,638,909 versus USD 934,787. Net loss was USD 3,420,884 versus USD 1,152,809, with a net loss attributable to non-controlling interests of USD 381,556 and preferred stock dividends of USD 83,068.

The filing's Acquisition note lists total Assets acquired of USD 23,585,590 against liabilities assumed of USD 13,622,968, including deferred consideration of USD 7,000,000 and a deferred tax Liability of USD 4,892,262.

The nine-month net loss of USD 19,899,879 compares with USD 3,410,700 a year earlier.

Nine-Month Results

For the nine months, the net loss was USD 19,899,879 versus USD 3,410,700. Total operating expenses were USD 19,709,913 versus USD 2,395,037, including a goodwill impairment of USD 10,070,124, general and administrative expenses of USD 8,998,785 and Research and Development of USD 641,004 versus USD 32,080.

Share-based compensation in general and administrative expenses totaled USD 1,907,250 for the nine months, including USD 582,500 tied to restricted stock unit vesting. The net loss attributable to non-controlling interests was USD 716,523.

Net loss attributable to common stockholders also reflects preferred stock dividends of USD 246,495 for the nine months versus USD 254,172, and the loss before the non-controlling interest adjustment is the USD 19,899,879 stated above.

Business Model and Balance Sheet

The company calls itself a "diversified technology and life sciences company" operating two reportable segments, one an artificial intelligence-driven energy technology Business focused on distributed energy resource optimization and grid-edge applications through Grid AI Corp.

Cash and cash equivalents were USD 239,834 versus USD 899,784 at December 31, 2025, and notes receivable were USD 2,964,000. Net cash used in Operating Activities was USD 4,668,243 versus USD 1,729,201, and loans and notes receivable advanced were USD 2,964,000. The filing states that these circumstances raise substantial doubt about the company's ability to continue as a going concern.

Accounts receivable, net, were USD 73,858 versus USD 29,974, other current receivables were USD 271,030 versus USD 1,309,053 and prepaid expenses were USD 321,419 versus USD 110,934. The filing's results discussion repeats that revenue of USD 38,110 for the quarter came primarily from the AI segment.

Items to Follow

Reference points include revenue from the AI segment, the cost base after the impairment, the collection of notes receivable and the Going Concern disclosure.

The nine-month results combine a small revenue base with large non-recurring and compensation items, so the filing's line-by-line detail on impairment, share-based compensation and non-controlling interests is the clearest guide to the cost base.